Silibinin, a flavonolignan with remarkable clinical efficacy against brain metastases in patients with ALK-rearranged NSCLC and capable of overcoming resistance to ALK-TKIs in vitro [76,77], protects the native lipidome of hepatic cells against the hyperlipidemic effects of lorlatinib and prevents lipid accumulation at therapeutically relevant concentrations. This evidence concerns the gene ALK and non-small cell lung carcinoma.